


# CD138+ Plasma Cell Enrichment to 92% purity directly from Bone Marrow

### **INTRODUCTION**

CD138 expression is a crucial marker in diagnosing plasma cell tumors and multiple myeloma cells. Traditionally, the evaluation of plasma cells from bone marrow involves a time-consuming and labor-intensive density gradient separation method using ficoll. However, this method leads to the loss of antigens, including CD138, from the plasma cell surface, necessitating immediate staining and analysis. This app note highlights the MARS® platform as a tool for efficient isolation of CD138+ plasma cells from unprocessed bone marrow samples. This innovative approach streamlines the isolation process, allowing for rapid and reliable analysis of CD138 expressing plasma cells.



## Positive CD138+ Cell Isolation from Bone Marrow

MARS® platform is a powerful solution for plasma cell isolation (Fig. 1) with:

- ✓ Very high cell purity and recovery
- ☑ Very high cell **viability**
- Minimal hands-on time
- Fast and easy workflow
- ✓ Column-free cell isolation
- Economical consumables
- Sterilizable, reusable fluidics

Figure 1. The MARS® platform offers a convenient and affordable method for isolating CD138+ cells. By employing an automated two-pass CD138+ enrichment process, the workflow improves the purity and maintains high recovery of plasma cells.

## MARS® Mag Premium Line

Learn More

A family of cell separation reagent kits with simple protocols for exquisitely easy, accelerated isolation and gentle sample treatment.





Figure 2. The MARS® platform offers an easy workflow for cells separation. A schematic showing a workflow: labeling protocol followed by two (or optionally three) MARS® Immunomagnetic isolation runs.

#### For research use only. Not for use in therapeutic or diagnostic procedures.

© Copyright 2023. All rights reserved. Applied Cells and MARS® are registered trademarks of Applied Cells, Inc. All other trademarks are the property of their respective owners.

AC\_A034C

